Table 2.
Summary of demographic and clinical variables as well as treatment modalities for female and male patients with breast cancer who received NAC (BCBaSe 3.0/NKBC, 2008–2019)
| Factors | Female (N = 6463), n (%) | Male (N = 24), n (%) | p value |
|---|---|---|---|
| Age in yrs, median (range) | 54 (21–83) | 64.5 (41–84) | 0.054 |
| Calendar year at diagnosis | |||
| 2008–2011 | 866 (13.4) | 3 (12.5) | 0.462 |
| 2012–2015 | 1706 (26.4) | 9 (37.5) | |
| 2016–2020 | 3891 (60.2) | 12 (50.0) | |
| Education Level | N = 6344 | N = 23 | 0.001 |
| Low ≦9 years | 965 (15.2) | 10 (43.5) | |
| Intermediate 10–12 years | 2576 (40.6) | 8 (34.8) | |
| High ≧13 years | 2803 (44.2) | 5 (21.7) | |
| Household Income | N = 6401 | N = 24 | 0.405 |
| Q4 | 2162 (33.8) | 9 (37.5) | |
| Q3 | 1611 (25.2) | 8 (33.3) | |
| Q2 | 1435 (22.4) | 2 (8.3) | |
| Q1 | 1193 (18.6) | 5 (20.8) | |
| Regions | N = 6420 | N = 24 | 0.715 |
| Northern | 408 (6.4) | 1 (4.2) | |
| Stockholm-Gotland | 2476 (38.6) | 10 (41.7) | |
| Uppsala-Örebro | 794 (12.4) | 1 (4.2) | |
| South | 1224 (19.1) | 7 (29.2) | |
| Southeast | 615 (9.6) | 2 (8.3) | |
| Western (Halland) | 903 (14.1) | 3 (12.5) | |
| Clinical T stage | N = 6463 | N = 24 | 0.951 |
| T 0–1 | 1066 (16.5) | 4 (16.7) | |
| T 2–4 | 5370 (83.1) | 20 (83.3) | |
| Clinical N stage | N = 6463 | N = 24 | 0.407 |
| cN + | 3444 (53.3) | 16 (66.7) | |
| cN- | 2978 (46.1) | 8 (33.3) | |
| Histological grade | N = 2394 | N = 11 | 0.054 |
| Well differentiated (G1) | 266 (11.1) | 1 (9.1) | |
| Moderately differentiated (G2) | 1357 (56.7) | 10 (90.9) | |
| Poorly differentiated (G3) | 771 (32.2) | 0 (0) | |
| Subtype according to IHC | N = 6463 | N = 24 | 0.001 |
| Luminal | 2942 (45.4) | 20 (83.3) | |
| Her2 positive | 2147 (33.2) | 4 (16.7) | |
| TNBC | 1374 (21.3) | 0 (0.0) | |
| Morphological | N = 2337 | N = 11 | 0.349 |
| Ductal | 1961 (83.9) | 11 (100) | |
| Lobular | 262 (11.2) | 0 (0.0) | |
| Other | 114 (4.9) | 0 (0.0) | |
| Breast surgery | N = 6463 | N = 24 | 0.001 |
| Breast conserving surgery | 2132 (33) | 0 (0.0) | |
| Mastectomy | 4331 (67) | 24 (100) | |
| Axillary surgery | N = 6271 | N = 23 | 0.756 |
| Sentinel lymph node dissection (SLND) | 1575 (25.1) | 5 (21.7) | |
| Axillary lymph node dissection (ALND) | 3912 (62.4) | 16 (69.6) | |
| SLND = > ALND | 784 (12.5) | 2 (8.7) | |
| Type of chemotherapy | |||
| Anthracycline- and taxane-based | 4858 (75.2) | 18 (75.0) | 0.817 |
| Anthracycline-based | 1004 (15.5) | 3 (12.5) | |
| Taxane-based | 601 (9.3) | 3 (12.5) | |
| Anti-HER2 treatment | |||
| Trastuzumab | 1917 (29.7) | 4 (16.7) | 0.101 |
| Adjuvant radiotherapy | N = 6463 | N = 24 | 0.629 |
| Yes | 4854 (75.1) | 17 (70.8) | |
| No | 1609 (24.9) | 7 (29.2) | |
| Adjuvant endocrine therapy | N = 6463 | N = 24 | < 0.001 |
| Yes | 3853 (55.4) | 22 (91.7) | |
| No | 2880 (44.6) | 2 (8.3) |
Bold text indicates a statistically difference with a p-value less than 0.05